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Abstract
Women with a documented deleterious mutation in BRCA1 or BRCA2 are at substantially elevated 
risk for ovarian cancer. To understand what percentage of women with high risk family histories 
know their risk is elevated we surveyed 1,885 women with a high or moderate risk family history 
and no personal history of breast or ovarian cancer, and asked about their perceived risk of breast 
and ovarian cancer. Among high-risk women, fewer than 20% reported use of genetic counseling, 
and knowledge of elevated risk of ovarian cancer was low. Prior genetic counseling was 
associated with greater perceived risk for ovarian cancer. Results suggest that most high-risk 
women (> 75%) do not know their risk for ovarian cancer. Identification of potentially high-risk 
women for referral to genetic counseling may improve informed ovarian cancer risk management.
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Women with a family history of breast or ovarian cancer suggestive of a deleterious 
mutation in one of two genes known as BRCA1 and BRCA2 are at substantially elevated risk 
of being diagnosed with and dying from breast and ovarian cancer (1, 2). A strong family 
history of breast cancer may suggest a risk of carrying a BRCA mutation, and estimates of 
the lifetime risk of ovarian cancer among BRCA mutation carriers range from 16 to 45% (3, 
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4). Unfortunately, unlike breast cancer, most (85%) ovarian cancer diagnoses occur at late 
stage when disease has spread and prognosis is poor; only 27% of women with advanced 
disease at diagnosis survive 5 years (5). Surgical prevention can reduce a high-risk woman’s 
risk for both breast and ovarian cancer, and is recommended for women known to be at high 
hereditary risk (6). As early diagnosis is associated with better prognosis, screening is 
recommended for high risk women who seek to delay or avoid surgery even though it has 
not been shown to be efficacious (1, 2).
Education about hereditary cancer risk and provision of genetic testing to identify women 
with deleterious mutations can be provided by a woman’s primary care physician or some 
other provider. In large hospital and academic setting this information is often provided by 
specialty genetic counselors who provide risk information and counseling, order appropriate 
genetic testing, and explain options including surgical prophylaxis to reduce cancer risk (7, 
8). Specialist counselors may be particularly important when a hereditary condition 
potentially causes cancer at multiple sites, as is the case with BRCA1 and BRCA2 mutations. 
In such cases, a medical professional may need adequate time to provide a patient with 
information about multiple cancer risks, screening tests, and prevention options.
Options available to reduce risk of getting or dying from ovarian cancer (9) include several 
kinds of surgery, chemoprevention, and screening. Prophylactic bilateral risk-reducing 
salpingo-oophorectomy (RRSO) can greatly reduce the risk of ovarian cancer among BRCA 
mutation carriers (RR 0.04 for ovarian cancer) (10), as may surgery to remove fallopian 
tubes and tubal ligation. Some surgical approaches may not be acceptable options for 
women who have not yet completed their families (9), or who want to retain ovarian 
function (11). Although it has not been shown to reduce mortality (12–15), intensive ovarian 
cancer screening through high-risk screening programs is often recommended for mutation 
carriers who have chosen to delay surgery and retain their ovaries (15, 16). Such programs 
usually include annual or more frequent measurement of serum CA125 and/or transvaginal 
ultrasound. Screening and surgery can also be used to reduce breast cancer risk for these 
women. Screening options for high-risk women include frequent mammograms starting at 
younger ages, and use of Magnetic Resonance Imaging (MRI). Surgical removal of breasts 
or ovaries also reduces risk of breast cancer by approximately 50% (10).
This study examined the hypothesis that many women with a family history of breast cancer, 
although aware of their risk for breast cancer may, unless specifically informed, be unaware 
of their potentially elevated risk for ovarian cancer (17). Risk perception for breast cancer is 
well studied (18–20), but few studies have examined high-risk women’s awareness of and 
beliefs about ovarian cancer risk, or use of services that may reduce risk of ovarian cancer. 
Low rates of awareness of ovarian cancer risk and very low rates of use of ovarian cancer 
screening (less than 10%) among those at high risk due to family history were reported (17) 
in 2002–2003 when genetic education and testing regarding BRCA1/2 risk had only recently 
become available. That study noted that knowledge of ovarian cancer risk among women, 
including those at high risk, was low (75% of high-risk women reporting have heard or read 
little about ovarian cancer); awareness was somewhat higher among women with a family 
history including ovarian cancer. Since then, use of genetic counseling has increased greatly 
but although studies have described some outcomes of genetic counseling, no studies have 
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reported on uptake of ovarian cancer screening and surgical prevention services by high-risk 
women.
In this study, we examine awareness and beliefs about ovarian cancer risk in a sample of 
women with a family history of breast cancer who had a mammogram during a 28-month 
window at a local multi-campus tertiary care institution with a large oncology program. We 
hypothesized that women’s lay theories of hereditary disease may focus primarily on the 
disease their family members actually had. This would mean that although women with a 
family history of breast cancer are likely to be aware of their elevated risk for breast cancer, 
their awareness of their ovarian cancer risk might be low, unless they had a family history of 
ovarian cancer or had previously participated in genetic counseling. As surgery and 
screening are recommended for mutation carriers and for women from high-risk families 
who choose not to undergo genetic testing, we also sought to identify factors associated with 
the use of ovarian cancer screening tests (CA125 blood tests and ultrasound) and interest in 
risk-reducing surgery. Surgery and screening are recommended for mutation carriers and for 
women from high-risk families who choose not to undergo genetic testing.
Materials and Methods
Participant identification, recruitment and eligibility
Participants in this study were a subset of those identified for possible participation in a 
randomized controlled trial (RCT) (www.ClinicalTrials.gov, # NCT01851109), designed to 
test the effect of offering genetic counseling on rates of RRSO among high-risk women. 
Family history data collected routinely and stored in a Mammography Reporting System© 
(MRS) database were used to identify women who received a mammogram between January 
2006 and April 2008 at any of three facilities at the Swedish Medical Center in Seattle, WA. 
Women between 35–80 years old who reported a personal or family history of breast cancer, 
no prior ovarian cancer diagnosis and no prior surgeries to remove their ovaries, were sent 
an invitation to participate, a consent form for the screening questionnaire, and a 3-page 
questionnaire to determine study eligibility. The questionnaire was used to assess risk of a 
BRCA1 or BRCA2 mutation and associated eligibility for the RCT. Data collected included 
age at diagnosis for women with a personal history of breast cancer, male relatives with 
breast cancer, family history of ovarian cancer, and Ashkenazi Jewish ancestry, which were 
not available in the MRS database. Women were told that they were selected for contact by 
the research program based on their past participation in the mammography program, and 
that they might be offered the opportunity to participate in cancer research based on their 
survey results. All study procedures were reviewed and approved by the Human Subjects 
Internal Review Boards of the Fred Hutchinson Cancer Research Center and Swedish 
Medical Center in Seattle, WA.
A total of 12,918 consent forms and questionnaires were mailed, of which 560 were returned 
by the post-office and the woman could not be contacted. From the remaining 12,358, 2,755 
questionnaires were completed and returned with consent forms for a study response rate of 
23%. For the current report, 870 of the respondents were excluded due to prior breast or 
ovarian cancer, prior ovarian surgery or missing data (details provided in results). Women 
with prior breast and ovarian cancer were excluded because they would be expected to have 
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very different levels of worry about their cancer risk than unaffected women. The remaining 
1,885 were included in the current study, including 738 RCT-eligible women classified as 
“high-risk” based on a pedigree warranting referral to genetic counseling, and 1147 RCT-
ineligible women classified as “moderate-risk” based on at least one first or second degree 
relative with breast or ovarian cancer.
For the current report, women were considered high-risk if they met NCCN V4.2013 Breast 
and Ovarian Cancer Genetic Assessment Guidelines recommendation for referral to a 
genetics professional, except that due to data limitations, family history of non-breast or 
ovarian cancers or in 3rd degree relatives were not specifically included. To ensure that high-
risk women were not missed, also included were women reporting 1) a deleterious mutation 
in BRCA1, BRCA2, or TP53, positivity for hereditary nonpolyposis colon cancer (HNPCC), 
or a first or second degree relative positive for HNPCC; 2) Ashkenazi Jewish ancestry with 
any family history of breast cancer among first or second degree relatives; and 3) a first 
degree relative, or multiple second degree relatives with breast cancer diagnosed before age 
50. Characteristics of women associated with classification as high risk are detailed in 
Figure 1.
Survey Measures
The questionnaire included an assessment of each woman’s personal history of ovarian and 
breast cancer and oophorectomy status to determine eligibility. Women provided detailed 
family history information about whether or not their mother, grandmothers, sisters, 
daughters, paternal and maternal aunts, and nieces had ever had breast cancer and if so 
whether or not the diagnosis occurred before age 50. Women were also asked if any of these 
female relatives had ever had ovarian cancer, and if any of their male relatives had been 
diagnosed with breast cancer. Women were also asked to indicate their race and whether or 
not they were of Ashkenazi Jewish ancestry.
Women were queried about their awareness of breast and ovarian cancer in terms of how 
much they had read or heard about each cancer. Response categories for these questions 
include “very little,” “some,” “a fair bit,” and “a lot” (17, 20, 21). Women were also asked 
to indicate if they felt their chances of getting each cancer compared to other women their 
age was “much lower”, “a little lower”, “about the same”, “a little higher”, or “much 
higher”. These items have been used in prior studies (17, 20, 21).
To measure prior awareness of risk for inherited susceptibility, women were asked if they 
had ever received genetic counseling and if they had CA125 assessed and/or pelvic 
ultrasound done regularly to screen for ovarian cancer. To measure interest in risk-reducing 
surgeries, women were asked whether they would consider having their breasts removed to 
decrease their risk of getting cancer, and if they would consider having their ovaries 
removed to decrease their risk of getting cancer. For all of these questions, women were 
given the response categories “definitely not,” “probably not,” “probably yes,” and 
“definitely yes.”
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Worry about cancer risk
Worry about breast and ovarian cancer risk was assessed using modified versions of the 
Lerman cancer worry scale, which was developed for the purpose of assessing worry about 
breast cancer and has been used with women at high risk for cancer due to family history 
(22). This measure has been reported to have internal consistency equivalent to a 
Cronbach’s alpha of .63 (22).
The scales for breast and ovarian cancer worry used in this work were modified from those 
described in the original publication primarily in how they are scored. The three questions 
asking about 3 aspects of cancer worry are the same as in the original publication for the 
breast cancer scale and differ only with reference to ovarian cancer for the ovarian cancer 
worry scale. They ask about worry during the past month, including (question #1) the 
frequency with which women worry, (question #2) the frequency with which thoughts about 
cancer affect mood, and (question #3) whether worry affects ability to perform daily 
activities. Responses to each item include “Not at all or rarely”, “Sometimes”, ”Often”, and 
“almost all the time”. From these responses, women’s levels of cancer worry were 
categorized as “Not worried” if they responded “Not at all or Rarely” to all three questions, 
“Mild” if they responded with “sometimes” to question #1, “Moderate” if they responded 
with “often” or greater to question #1 or “sometimes” to question #2, and “Severely” if they 
responded with “often” or greater to question 2 or “sometimes” or greater to question #3. 
This coding method has been used for both the breast and ovarian cancer versions of the 
modified scale and has been reported in prior studies (17, 19, 23, 24).
In addition to the categorical worry scales, we use a Rasch Model (25) to create a monotonic 
linear measure of worry with respect to each cancer based on the same items (19). The 
resulting monotonic scores increase with increasing levels of worry. The Rasch modeling 
process takes into account that differences in adjacent categories may represent different 
changes in the level of worry, allowing for the creation of a linear scale result that can be 
used in statistical models such as ordinary least squares regression that expect linear 
responses. While the Rasch score is useful for measuring worry in a continuous manner, it is 
not easily interpretable, in part because a standardized unit for worry does not exist.
Analysis
We examined the association between ovarian cancer risk (moderate vs. high) and 
awareness of each cancer, perceived risk, worry, awareness of genetic counseling, use of 
genetic counseling, and use of screening tests using descriptive analyses. Categorical and 
Boolean variables were compared across groups using Fisher’s exact test, and continuous 
variables were compared using Student’s t-test. All analyses were conducted using the R 
statistical language (26). Multivariable regression analyses were conducted to examine the 
degree to which the presence of ovarian cancer in a woman’s family history and use of 
genetic counseling were associated with: awareness of each cancer, perceived risk and worry 
about risk for each cancer, and reported prior use of screening and risk reduction services. 
Finally, within the high-risk population, we examined the degree to which prior participation 
in genetic counseling was associated with beliefs about risk, worry about risk, use of 
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screening including CA125 blood tests and transvaginal ultrasound (TVU), and interest in 
risk reduction services.
Results
Out of the 2,755 survey respondents, women with a personal history of breast (n=652) or 
ovarian (n=6) cancer, without ovaries (n=135), without a family history of breast or ovary 
cancer (n=133), or who failed to respond to any of these questions (n=42) were excluded 
from this analysis, some for multiple reasons. Among the 1,885 included respondents, 1,147 
(60.8%) were considered to be at moderate-risk and 738 (39.1%) at high-risk as defined 
above. Of the 738 high-risk women, 14 (1.9%) did not provide definitive data on their prior 
use of genetic counseling (1.2% indicated that they were “not sure” whether they had 
attended counseling, and 0.7% did not answer the question) and were excluded from 
analyses regarding genetic counseling. Twenty three moderate-risk women also failed to 
provide definitive data on their use of genetic counseling (9 women indicated they were “not 
sure” and were treated as “no counseling” and 14 women did not answer the question and 
were dropped from analyses using this variable). Demographic characteristics of the 
moderate and high-risk respondents are reported in Table 1. Moderate- and high-risk women 
did not differ significantly with respect to age or in self-reported race, although high-risk 
women were more likely to report Hispanic ethnicity. Consistent with risk classification 
criteria, high-risk women were more likely to report a family history of ovarian cancer and 
having Ashkenazi Jewish heritage.
High-risk women were significantly more likely than moderate-risk women to report 
awareness of breast cancer (having read or heard “a bit” or “a lot” about a cancer) and of 
genetic counseling and testing, and perceiving their risk for breast cancer to be higher than 
that of others their age (65.7% vs 42.1%; p < 0.05). In contrast, levels of ovarian cancer 
awareness were low when compared to levels of breast cancer awareness. Approximately 
21.8% of high-risk women perceived their risk for ovarian cancer to be higher than average, 
as did 7.4% of moderate-risk women. High-risk women were also significantly more likely 
than moderate-risk women to report themselves as candidates for genetic testing and to have 
participated in genetic testing and counseling (Table 1). High-risk respondents were more 
likely than those at moderate-risk to report “Probably Yes” or “Definitely Yes” for regular 
CA125 testing (15.9% versus 11.6%; p < 0.05), and regular TVU (11.7% versus 5.1%; p < 
0.05). Willingness to consider surgical prophylaxis for either breast or ovaries did not differ 
between high- and moderate-risk respondents. Consistent with other studies, removal of 
ovaries was rated more acceptable than prophylactic mastectomy by our study participants 
(51% reported willingness to consider ovarian removal and 32% mastectomy). Willingness 
to consider removal of ovaries did not vary by age in this sample, but this may reflect the 
fact that only 6% of our participants were under 40 years of age, and none were under 35. 
Many had likely completed their families.
We compared levels of cancer worry using the categorical evaluation previously described 
to the continuous measure obtained from a linear rating scale model. There was a strong 
association between the categorical and the continuous methods of coding the scales for both 
breast and ovarian cancer (Figure 2 & 3): women categorized to higher levels of worry 
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tended to have higher scores on the linear worry scale. There was considerably more spread 
in the linear scale among those categorized as moderately and highly worried than among 
women who indicated milder levels of worry.
Factors associated with elevated levels of awareness, perceived risk and worry about cancer 
risk, including prior genetic counseling and a family history of ovarian cancer, are reported 
in Table 2. The differences in scores for each variable are reported for those with and 
without the associated factor. Both genetic counseling and a family history of ovarian cancer 
were associated with higher awareness of ovarian cancer, perceived risk for ovarian cancer, 
and use of the ovarian cancer screening tests CA125 and TVU (p<0.05). Family history of 
ovarian cancer was also associated with greater worry about ovarian cancer risk (p<0.05). 
Prior genetic counseling was associated with self-reported awareness of breast cancer, 
perceived risk of breast cancer, and worry about risk for breast cancer (p<0.05). Having a 
family history of ovarian cancer, which is associated with an elevated risk for having a 
BRCA1/2 mutation, was associated with less self-reported awareness of breast cancer 
(p<0.05), and with lower reported use of mammography for breast cancer screening 
(p<0.05).
Prior use of genetic counseling was twice as high among high-risk versus moderate-risk 
women (14.8% vs 6.5%; p=<0.001), but low in both groups (Table 3). In the subgroup of 
724 high-risk women, prior participation in genetic counseling was associated with a greater 
proportion reporting that they were aware, having heard or read “a fair bit” or “a lot”, about 
breast cancer (p<0.001), ovarian cancer (p<0.001) and genetic testing (p<0.001). Only 
40.4% of high-risk women who had attended genetic counseling, and 26.4% of those who 
had not, reported having heard or read “a fair bit” or “a lot” about ovarian cancer, while a 
majority of the women who reported prior genetic counseling also reported awareness of 
breast cancer (87.2%) and genetic testing (67.5%). Among the high-risk women, genetic 
counseling was also associated with significantly increased levels of perceived risk for both 
breast (p<0.003) and ovarian cancer (p<0.001), increased use of ovarian cancer screening 
including CA125 (p<0.003) and TVU (p<0.001), and increased willingness to consider 
undergoing prophylactic surgery to reduce risk for both breast and ovarian cancer (p<0.01).
Discussion
This study included women with any family history of breast or ovarian cancer but no 
personal history of either cancer, and subdivided them into high-risk women with pedigrees 
likely to warrant genetic counseling and moderate-risk women with pedigrees unlikely to be 
associated with a deleterious mutation. We postulated that lay theories of hereditary illness 
focus on the specific illnesses presenting in one’s family, and that without education or 
counseling other illnesses related to a deleterious mutation would be ignored. Thus, we 
hypothesized ovarian cancer risk would not be a focus of awareness or activity among 
women at risk for a BRCA1/2 mutation based on a family history of breast cancer alone. We 
found that although the majority of women reported having read or heard “a fair bit” or “a 
lot” about breast cancer, less than a third reported similar awareness of ovarian cancer. In 
addition, although high levels of worry about cancer risk have been reported among women 
with a family history of breast cancer, particularly those seeking genetics services (19, 27) 
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few studies have focused on worry about ovarian cancer. We found that rates of awareness 
and worry in this population were moderately elevated in a majority of high-risk women 
only for breast cancer. Reported levels of awareness of ovarian cancer and of the possibility 
of elevated levels of risk, even among those with significant family histories, were quite 
modest (19, 28). Even among the high-risk women, while most were aware of being at 
elevated risk for breast cancer, fewer than 25% reported awareness of elevated risk for 
ovarian cancer.
Use of mammography was very high in this sample based on the recruitment strategy used, 
which included only women with a family history of disease who had received at least one 
recent mammogram. In this population selected for use of cancer screening, use of ovarian 
cancer screening services was appropriately modest among moderate-risk women. These 
screening tools have not been shown to reduce mortality in either moderate- or high-risk 
groups (15), but ovarian cancer screening is recommended for high-risk women who have 
not had genetic testing and those with mutations who forego or postpone RRSO.
Only 15% of the women in this sample at high risk for a mutation reported having received 
genetic counseling prior to the survey. High-risk women who had not received genetic 
counseling appeared to be unaware of their potentially elevated risk of ovarian cancer 
although aware of their potentially elevated breast cancer risk. Among high-risk women, 
those with prior genetic counseling demonstrated higher levels of awareness and knowledge 
about ovarian cancer, were more likely to use screening, and reported greater willingness to 
consider preventive services, suggesting that genetic counseling may increase awareness of 
ovarian cancer risk and willingness to consider prophylactic risk-reducing surgery, or that 
women considering these options are more likely to seek genetic counseling. This finding is 
consistent with prior studies examining the effectiveness of genetic counseling for high risk 
women on breast cancer knowledge (27, 29), but unique in that most prior studies have 
focused on perceived risk and knowledge of breast and not ovarian cancer.
It is encouraging that the association of genetic counseling with increased awareness and use 
of risk reduction services is not accompanied by increased worry about ovarian cancer. 
Given high rates of worry about breast cancer risk in this population and ovarian cancer’s 
poor prognosis, information about ovarian cancer risk could potentially increase women’s 
levels of worry about cancer and act as a barrier to risk reduction. However, we found that 
among women with a family history of breast or ovarian cancer, prior genetic counseling 
was not associated with ovarian cancer worry. Prior use of genetic counseling was 
associated with elevated levels of worry about breast cancer but this may be due to high-risk 
women seeking counseling because of worry about breast cancer risk associated with their 
family history (19, 28). Within the high-risk population, prior genetic counseling was 
associated with a trend toward increased levels of worry about risk for ovarian cancer, but 
levels of worry were very modest in the counseled group. Very few women reported 
moderate or severe worry about ovarian cancer.
The finding that women with a family history of ovarian cancer were both more likely to use 
ovarian cancer screening services and simultaneously LESS likely to report high levels of 
awareness of and perceived risk for breast cancer was unexpected given that these women 
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also had a family history of breast cancer. We can only speculate that because of its poor 
prognosis, ovarian cancer is more likely than breast cancer to have resulted in the death of a 
relative, causing concern about ovarian cancer risk to partially eclipse concern about breast 
cancer risk. Further study of this phenomenon could be of interest in understanding coping 
with hereditary cancer risk syndromes associated with cancer at multiple organ sites.
Limitations
The 23% response rate for the survey introduces the possibility of selection bias. Because 
our purpose was recruitment for a RCT, only motivated women were of interest. Women 
who completed the survey without any reminder may be more organized, interested in 
medical care generally, and more compliant than those who did not. We hope that selection 
bias with respect to cancer worry was minimal because the study materials did not mention 
risk, suggesting only that the survey was an opportunity to participate in women’s cancer 
research. Dependence on self-report without chart review to confirm family history and use 
of services introduces the possibility of recall bias. Studies of self-report data on 
mammography use and on family histories of breast cancer in first degree relatives have 
found these reports to be sufficiently accurate for comparative research of this sort (30, 31). 
The validity of self-reports of CA125 blood tests and TVU imaging are unknown.
In addition, this study was conducted in an urban/suburban area in a single region of the 
U.S.A. where the population is generally well educated, predominantly white, and likely 
insured. The participating women had all received mammograms within the previous 28 
months at facilities associated with a large hospital offering both specialty genetic 
counseling and an ovarian cancer-screening program for high-risk women. The metropolitan 
area also includes both a large managed care system and an academic medical center that 
provide specialty genetic counseling for high-risk women. Inclusion of three facilities in 
different parts of the city may somewhat improve generalizability, but results may overstate 
the levels of knowledge regarding risk for ovarian cancer, and use of genetic counseling and 
ovarian cancer screening, relative to those found in future studies in other parts of the 
country where similar services are less available.
Finally, we did not identify, even through self-report, women who had had genetic testing 
prior to the study. This omission may have led to classification of a few women as high-risk 
who, though possessing a high-risk family history, had previously tested negative for a 
deleterious mutation and knew themselves to be at closer to average risk. Such individuals 
are likely to be few, but they are possible. We also excluded women who had had prior 
surgery to remove their ovaries; accordingly we cannot report on the likelihood of RRSO 
following genetic counseling or on views of women who elect RRSO. The significant 
association of prior genetic counseling with reported use of CA125 and TVU tests as 
screening tests for ovarian cancer suggests that counseling may increase use of at least some 
services intended to reduce risk of ovarian cancer death in high-risk women.
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Conclusion
Overall, these findings suggest that high-risk women are largely unaware of their risk for 
ovarian cancer and that only about a fifth of high-risk women have received genetic 
counseling. Identification of high-risk women and referral for genetic counseling could 
improve high-risk women’s ability to make informed decisions regarding use of ovarian 
cancer risk-reducing strategies including prophylactic surgery and use of screening tests. 
Physicians caring for high-risk women have an opportunity to assure that their patients 
receive services that will help them reduce their risk of having and dying of both breast and 
ovarian cancer. It appears that without explicit education, women with a strong family 
history of breast cancer are often unaware of the ovarian cancer risk associated with a 
BRCA1/2 mutation. When a mutation is associated with cancer at multiple sites, educational 
efforts may be particularly important.
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Figure 1. 
High-risk Criteria.
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Figure 2. 
Association between Rasch model scores for breast cancer worry and the categorical breast 
cancer worry scale results.
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Figure 3. 
Association between Rasch model scores for ovarian cancer worry and the categorical 
Ovarian Cancer worry scale results.
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Table 1
Demographics, Perceptions of Risk, Self-reported Awareness and Candidacy for Genetic Testing by Risk 
Level
Question Response Category
Risk Level
p-valueModerate High
Number of Participants 1147 738
Years of Age Mean (SD) 53(10) 52(11) 0.798
Race White/Caucasian 93.5% 92.1%
Other 0.9% 1.9%
Asian 3.8% 3.1%
American Indian/Alaska Native 0.4% 0.5%
Black or African American 1.0% 1.9%
Native Hawaiian or other Pacific 
Islander 0.3% 0.3% 0.331
Hispanic Ethnicity 2.0% 5.7% 0.004
Ashkenazi Jewish 0.7% 24.1% < 0.0005
Family history of ovary cancer * 3.1% 22.0% < 0.0005
Family history of breast cancer * 99.0% 97.7% 0.030
Attended prior genetic counseling 6.5% 14.8% < 0.0005
Chances of getting breast cancer compared to women my age 
are:
Lower 21.7% 10.1%
About the same 36.2% 24.3%
Higher 42.1% 65.7% < 0.0005
Chances of getting ovarian cancer compared to women my age 
are:
Lower 33.5% 19.9%
About the same 59.2% 58.3%
Higher 7.4% 21.8% < 0.0005
How much have you read or heard concerning breast cancer? Very little/None 3.7% 2.2%
Some 31.0% 26.8%
A fair bit 36.1% 37.0%
A lot 29.1% 34.0% 0.021
How much have you read or heard concerning ovarian cancer? Very little/None 26.8% 28.7%
Some 45.8% 42.9%
A fair bit 20.1% 19.5%
A lot 7.3% 9.0% 0.375
How much have you read or heard concerning genetic testing? Almost nothing 28.8% 21.7%
Relatively little 48.2% 45.2%
A fair bit 21.1% 27.5%
A lot 1.9% 5.6% < 0.0005
Would you Consider prophylactic breast surgery? Definitely not 23.9% 21.9%
Probably not 45.5% 45.5%
Probably yes 23.5% 22.6%
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Question Response Category
Risk Level
p-valueModerate High
Definitely yes 7.2% 10.0% 0.185
Would you Consider prophylactic ovarian surgery? Definitely not 16.8% 17.9%
Probably not 32.6% 30.2%
Probably yes 32.5% 32.4%
Definitely yes 18.1% 19.6% 0.657
Have you had CA125 tests done regularly for ovarian cancer? Definitely not 62.6% 61.0%
Probably not 25.8% 23.1%
Probably yes 7.6% 7.9%
Definitely yes 4.0% 8.0% 0.003
Have you had ultrasound tests done regularly for ovarian cancer? Definitely not 79.4% 75.5%
Probably not 15.5% 12.7%
Probably yes 2.6% 5.5%
Definitely yes 2.5% 6.2% < 0.0005
*
Family history defined as one or more affected first or second degree relative.
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Table 3
Ethnicity, Family History, Perceptions of Risk, Self-reported Awareness and genetic counseling among High 
Risk women (n=724) by self-reported prior genetic counseling
Question Response
Reported Prior Genetic Counseling
p-valueNo Yes
615 109
FH of Ovary Cancer (1 or more) Yes 22.8% 16.5% Ns
Chances of getting BC compared to women my age are: Lower 10.7% 6.5%
About the same 26.4% 13.9%
Higher 62.8% 79.6% 0.003
Chances of getting OC compared to women my age are: Lower 20.8% 16.3%
About the same 60.3% 46.2%
Higher 18.9% 37.5% <0.001
How much have you read or heard concerning Breast Cancer Very little/None 2.6% 0.0%
Some 29.1% 12.8%
A fair bit 37.6% 34.9%
A lot 30.6% 52.3% <0.001
How much have you read or heard concerning Ovarian Cancer Very little/None 30.6% 18.3%
Some 43.1% 41.3%
A fair bit 19.4% 21.2%
A lot 7.0% 19.2% 0.001
How much have you read or heard concerning genetic testing Almost nothing 24.5% 7.4%
Relatively little 48.6% 25.0%
A fair bit 24.5% 44.4%
A lot 2.4% 23.1% <0.001
Categorical Ovarian Cancer Worry Scale Not Worried 468 (76.9%) 82 (75.9%)
Mild 88 (14.5%) 13 (12.0%)
Moderate 35 (5.8%) 8 (7.4%)
Severe 18 (3.0%) 5 (4.6%) Ns
Categorical Breast Cancer Worry Scale Not Worried 256 (42.1%) 23 (21.1%)
Mild 201 (33.1%) 49 (45.0%)
Moderate 121 (19.9%) 28 (25.7%)
Severe 30 (4.9%) 9 (8.3%) <0.001
Would you consider having your breasts removed to decrease the risk 
of getting breast cancer?
Definitely not 139 (23.8%) 11 (10.3%)
Probably not 265 (45.3%) 51 (47.7%)
Probably yes 128 (21.9%) 28 (26.2%)
Definitely yes 53 (9.1%) 17 (15.9%) 0.004
Would you consider having your breasts removed to decrease the risk 
of getting ovarian cancer?
Definitely not 114 (19.0%) 11 (10.4%)
Probably not 185 (30.9%) 29 (27.4%)
Probably yes 193 (32.2%) 36 (34.0%)
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Question Response
Reported Prior Genetic Counseling
p-valueNo Yes
Definitely yes 107 (17.9%) 30 (28.3%) 0.026
Have regular CA125 tests? Definitely not 368 (62.2%) 61 (56.5%)
Probably not 140 (23.7%) 20 (18.5%)
Probably yes 47 (7.9%) 8 (7.4%)
Definitely yes 37 (6.3%) 19 (17.6%) 0.003
Have regular ultrasounds of ovaries? Definitely not 468 (77.5%) 71 (65.7%)
Probably not 77 (12.8%) 13 (12.0%)
Probably yes 33 (5.5%) 5 (4.6%)
Definitely yes 26 (4.3%) 19 (17.6%) <0.001
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